Latest News and Press Releases

Data published in bioRxiv shows AMP-vaccination significantly enhanced TCR-T cell anti-tumor response, while also inducing epitope spread among the endogenous T cell population, leading to durable...

The ELI-002 and Libtayo® combination will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally...

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases,...

Data shows that AMP-vaccination significantly enhanced TCR-T cell anti-tumor response while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid...

ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primatesPrime-boost administration of...

AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence ...

The Company has moved from Cambridge, MA to a new, larger space in the Seaport District, Boston’s growing biotech hubEnrollment continues for the multicenter Phase 1 AMPLIFY-201 study of the lead...

Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor modelAMP boosting of...

The first patient was dosed at MD Anderson as part of a multicenter clinical trial to evaluate the safety and efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine, in...

ELI-005, containing the Amphiphile vaccine adjuvant AMP-CpG, induced >25-fold higher antigen-specific T cells in the peripheral blood and exhibited potent killing of antigen-positive targets in...